• history;
  • erythropoietin;
  • recombinant protein;
  • anaemia;
  • renal failure;
  • cancer


  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

In the light of the enthusiasm regarding the use of recombinant human erythropoietin (Epo) and its analogues for treatment of the anaemias of chronic renal failure and malignancies it is worth remembering that today's success has been based on a century of laborious research. The concept of the humoral regulation of haematopoiesis was first formulated in 1906. The term ‘erythropoietin’ for the erythropoiesis-stimulating hormone was introduced in 1948. Native human Epo was isolated in 1977 and its gene cloned in 1985. During the last 15 yr, major progress has been made in identifying the molecules controlling Epo gene expression, primarily the hypoxia-inducible transcription factors (HIF) that are regulated by specific O2 and oxoglutarate requiring Fe2+-containing dioxygenases. With respect to the action of Epo, its dimeric receptor (Epo-R) has been characterised and shown to signal through protein kinases, anti-apoptotic proteins and transcription factors. The demonstration of Epo-R in non-haematopoietic tissues indicates that Epo is a pleiotropic viability and growth factor. The neuroprotective and cardioprotective potentials of Epo are reviewed with a focus on clinical research. In addition, studies utilising the Epo derivatives with prolonged half-life, peptidic and non-peptidic Epo mimetics, orally active drugs stimulating endogenous Epo production and Epo gene transfer are reviewed.

The Biblical phrase ‘for the life of the flesh is in the blood’ (Moses 4th book; Leviticus 17:11) reveals that blood was considered a symbol of life in the early days. In fact, ancient medicine related almost all somatic and psychic diseases to disorders of the blood. Accordingly, the blood of a strong animal was believed to make a human recipient powerful and courageous, if ingested or used for a bath (1, 2). Interestingly, the ancient concept of blood as a medium transferring individual properties has recently received some verification with the curious finding that the chemosensory identity through odour is altered in rodents after bone marrow transplantation (3). The first blood transfusion in a human being was performed by Jean-Baptiste Denis, Physician in Ordinary to Louis XIV, and the surgeon Paul Emmerez in Paris in 1667. Reportedly, a febrile young patient, who suffered from symptoms of anaemia after he had been bled 20 times for therapy, improved greatly following the transfusion of lamb blood (1). Both for medical and ethical reasons, heterologous blood transfusion to humans was disapproved after a few more trials. In 1825 James Blundell, an obstetrician in London, performed the first successful homologous blood transfusion in a human being, a woman suffering from postpartum haemorrhage whose husband donated the blood (4). Immune reactions and blood clotting remained major plagues in transfusion therapy. Following the discovery of the human blood groups and through the use of anticoagulants, homologous blood transfusion has become an important life-saving procedure in the previous century. The remaining risks include febrile non-haemolytic transfusion reactions, graft-vs.-host-disease, acute or delayed haemolytic reactions and transmission of prions, viruses, protozoans and bacteria. Thus, homologous blood cell transfusion should be avoided whenever possible.

Recombinant DNA technologies enabling the manufacture of biopharmaceuticals in cultured bacterial, yeast and animal cells have gained medical and economic relevance during the past 25 yr. Over 20 different blood cell-modulating proteins of potential therapeutic value have been engineered. Some of these are lineage-specific haematopoietic growth factors (Table 1), while others act primarily on the immune system. The growth factors inhibit apoptosis of haematopoietic stem cells and progenitors of blood cells. Red blood cell production is regulated by the glycoprotein hormone erythropoietin (Epo) which is mainly of renal origin. Before recombinant human Epo (rHuEpo) became available for therapy, about 25% of patients with chronic kidney disease (CKD) needed regular transfusions of red cells. rHuEpo is also administered for treatment of non-renal anaemias, such as those associated with malignant or autoimmune diseases, and in surgical settings.

Table 1.   Therapeutically relevant haematopoietic growth factors
FactorSize (kDa)Primary cells of synthesisPrimary target cellsClinical review
  1. 1 Routinely used as recombinant drugs.

  2. CKD, chronic kidney disease; BFU, burst-forming unit; CFU, colony-forming unit; CSF, colony-stimulating factor; E, erythroid; G, granulocyte; M, monocyte; Eo, eosinophilic granulocyte; Meg, megakaryocyte.

Erythropoietin130Renal fibroblasts, hepatocytesCFU-ECKD (305, 306, 351) Cancer (316, 352, 353)
Thrombopoietin60Hepatocytes, renal tubular cellsCFU-Meg, megakaryocytes, thrombocytes(354–356)
GM-CSF114–35T-lymphocytes, monocytes, endothelial cells, fibroblastsCFU-GM, CFU-G, CFU-M, CFUEo, CFU-Meg(357–364)
G-CSF120Monocytes, endothelial cells, fibroblastsCFU-G(357, 360, 361, 363, 364)

In the light of the therapeutic value of rHuEpo it should be remembered that today's success has been based on a century of laborious research into the basics of erythropoiesis. Apart from an anecdotal review, this article provides information on novel actions of Epo and pharmacological strategies for the treatment of anaemias.

Stimulation of erythropoiesis by hypoxaemia

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

In an elegant book chapters on very early observations of respiration at high altitudes, Allan Erslev (5) cites the Jesuit priest Father Acosta who, in 1569, noted breathlessness, dizziness and vomiting on highland expeditions (the elements of air are in this place so thin and delicate…). Still, the important role of red blood cells as O2 carriers was not recognised until the second half of the 19th century (Table 2). Paul Bert, Professor of Physiology at the Sorbonne in Paris, who later switched over to politics and became governor-general of French Indo-China (6), and his mentor Denis Jourdanet discovered that the concentration of red blood cells depends on the O2 supply to the tissue (7). In following the order of Napoleon III, Jourdanet had moved to the highlands of Mexico where he made his important observations on the symptoms of chronic mountain disease. The patients were found to have thickened blood, while their symptoms were similar to those of anaemic persons (dyspnoea, tachycardia and syncope). Jourdanet coined the term ‘anoxyhémie’ to describe the lack of O2 in arterial blood. Paul Bert noted that animals living in La Paz at 4000 m altitude have a higher haemoglobin concentration and thus higher O2 capacity than lowlanders (7). Bert and Jourdanet believed that polyglobulia, the ‘thick blood’ of high-altitude residents was inherited. Similarly, Gustav von Hüfner (Hüfner's number: 1 g haemoglobin binds 1.34 mL of O2) stated in 1890 that the increased haemoglobin richness of the blood was acquired through generations (8). In the same year, however, this concept was disproved by the French anatomist Francois-Gilbert Viault who had travelled from Bordeaux to the highland of Peru. After he had stayed in Morococha (about 4500 m above sea level) for 23 d, the number of erythrocytes in his blood was found to have increased from 5 to 8 × 106/μL. His companions showed the same reaction (Dr. Mayorga, a few miners, a dog, a rooster and a llama). Viault concluded that erythropoiesis is acutely stimulated when the O2 content of the blood is reduced (9). Along these lines, Müntz reported that the generations of a herd of rabbits he had brought to the Pic du Midi (2877 m) in the Pyrenees exhibited a 75% increase in the iron content of blood (10). Friedrich Miescher in 1893 (11) reported the data of his colleague Egger from Basel, showing that the number of red blood cells was increased in anaemic patients with tuberculosis after they had spent a few weeks in an alpine health resort. Miescher explained the stimulation of erythropoiesis by a reduced O2 partial pressure in the bone marrow.

Table 2.   Seminal studies of the respiratory function of red blood cells
1840Blood gas measurementsH. Gustav Magnus
1860Analysis of function of haemoglobinFelix Hoppe-Seyler
1870Tissue respirationAlexander Schmidt, Eduard F.W. Pflüger
1870Role of bone marrow in haematopoiesisErnst Neumann, Guilio Bizzozero
1880Respiratory function at high altitudePaul Bert, Denis Jourdanet
1890Haemoglobin/O2 binding curveChristian Bohr

The idea of hormonal regulation of erythropoiesis was first formulated by Paul Carnot, Professor of Medicine at the Sorbonne, Paris, and his co-worker Deflandre in 1906 (12, 13). These investigators had subjected rabbits to a bloodletting (30 ml), taken another blood sample on the next day and injected the serum (5–9 mL) into normal rabbits. The concentration of red blood cells in the recipients increased by 20–40% within 1–2 d. Carnot and Deflandre concluded that the serum contained a haematopoietic factor (hémopoiétine). The more specific name ‘erythropoietin’ was introduced by Eva Bonsdorff and Eeva Jalavisto from Helsinki in 1948 (14).

The search for the elusive hormone

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Extensive studies have shown that reticulocytosis occurs after a lag of 3–4 d, when the plasma Epo level increases (15). The concentration of red blood cells requires an even longer period to rise significantly. Thus, the results of Carnot and Deflandre (13) are almost impossible to reproduce in the described way. In addition, Carnot and Deflandre (13) reported that the ‘hémopoiétine’-containing serum was inactivated by heating to 56°C, whereas Epo is a heat-stable glycoprotein that loses little activity on short-term boiling. The observations made by Carnot and Deflandre (13) were probably based on good luck, i.e. haemoconcentration in the recipients. Yet this backward glance shows that a plausible concept may promote scientific progress even if derived from a misleading observation.

In the following 50 yr, some investigators reported that the injection of serum from anaemic or hypoxaemic animals increases the number of red blood cells in recipient animals (16–21); [for a review, see Ref. (22)]. Moreover, Oliva et al. published in 1949 that the transfusion of plasma (40–50 mL) from patients with pernicious anaemia to normal subjects led to reticulocytosis in the recipients within 12 h (23). Despite these reports, the existence of ‘hémopoiétine’ was doubted for many years because most investigations failed to reproduce Carnot's finding (24, 25). The interest in the alleged humoral erythropoietic factor was stimulated after Kurt Reissmann (26) and Gerhard Ruhenstroth-Bauer (27) demonstrated in 1950 that erythrocytic hyperplasia of the bone marrow and reticulocytosis occur in both partners of parabiotic animal pairs when anaemia or hypoxaemia is induced in one of them. Allan Erslev, who was born in Copenhagen in 1919 and later became Professor of Medicine at Thomas Jefferson University in Philadelphia, is generally credited with having provided definitive proof for the existence of Epo (28). Erslev transfused large volumes (50–200 mL) of plasma from anaemic rabbits (haematocrit <0.2) into normal rabbits. The recipients responded with significant reticulocytosis and, in the longer term, an increase in haematocrit values. Notably, Erslev predicted 50 yr ago the potential therapeutic value of the erythropoietic factor: ‘Conceivably isolation and purification of this factor would provide an agent useful in the treatment of conditions associated with erythropoietic depression, such as chronic infection and chronic renal disease’ (28).

The identification of the Epo-producing organs

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Observations of patients with a patent ductus arteriosus led to the finding that hypoxia of the lower part of the body causes polyglobulia (29, 30). The important role of the kidney in the production of Epo became clear when Leon Jacobson and his colleagues published in 1957 that nephrectomised rats fail to respond with the normal increase in the plasma Epo level on hypoxic stress (31). Subsequently, initial reports of low plasma Epo activity in anaemic patients with CKD appeared (32, 33). In 1961 Kuratowska et al. (34) and Fisher and Birdwell (35) detected erythropoietic activity in the blood perfusate of isolated rabbit kidneys and in situ perfused dog kidneys, respectively. Nevertheless, for many years it was doubted that renal cells synthesise Epo directly because attempts failed to extract Epo from the kidney. The alternative concept was put forward that hypoxic kidneys would release an enzyme (erythrogenin) capable of splitting Epo from a plasma protein (36). The erythrogenin concept was disapproved in 1974 when Erslev demonstrated Epo activity in isolated serum-free perfused rabbit kidneys (37). Subsequently, Epo (38, 39) and Epo mRNA (40–42) were extracted from the kidneys of hypoxic rodents. The hormone was shown to be mainly present in the renal cortex and not in the medulla (38). In situ hybridisation studies identified a subgroup of peritubular fibroblasts as the site of Epo gene expression in the kidney (43). In addition to the kidneys, liver, spleen, lung, bone marrow and brain were shown to express Epo mRNA (44–46). As in other mammals, the liver is the main site of Epo synthesis in human foetuses (47). Brain-derived Epo, which is unlikely to enter the general circulation in significant amounts because of the blood–brain barrier, is thought to act as a paracrine neuroprotective factor (48).

Isolation and chemical characterisation of Epo

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

The initially slow progress in Epo research is understandable in view of the low concentration of the hormone in fluids and tissues, which rendered its detection difficult (49). Normally 1 L of plasma contains about 50 ng Epo. Plzak et al. (50) first developed a reliable bioassay for Epo in which radioactive iron was injected into rats followed by measurements of the incorporation of the iron into haemoglobin. An increased sensitivity was achieved when the assay was carried out in polycythaemic mice, whereby polycythaemia was induced by blood transfusion (51) or previous hypoxia exposure (52) to suppress endogenous Epo production. One Epo unit (U) was defined as the dose producing the same erythropoiesis-stimulating response as 5 μmol cobaltous chloride in experimental animals. In 1966, Epo standard A (ESA; prepared from sheep plasma) was replaced by standard B, which was of human urinary origin and nominated as the first International Standard [IU; (53)]. In 1972, the second International Reference Preparation [2nd IRP; (54)] of impure human urinary Epo (specific activity 2 IU/mg protein) and in 1992 a purified recombinant DNA-derived human Epo [IS 87/684; 130 000 IU/mg fully glycosylated protein; (55)] were established. Garcia, Sherwood and Goldwasser first developed a reliable radioimmunoassay for Epo (56–58). Today, commercial enzyme-linked immunoassay kits are most commonly used for the measurement of Epo (59). The concentration of immunoreactive Epo in serum or plasma of non-anaemic humans amounts to about 15 IU/L.

The purification of human Epo was a difficult task. Based on their experience with the extraction of Epo from sheep plasma, Goldwasser and Kung (60) calculated in 1968 that a volume of 3250 L of urine from anaemic patients was required to purify 10 mg pure human Epo, which ‘would represent about 3 yr's daily collection from a single patient, or one month's collection from 36 patients, which does not seem to be an impossible goal.’ The authors succeeded after 9 yr (61). The pure human urinary Epo enabled the partial identification of its amino acid sequence and the subsequent isolation of the human Epo gene (62, 63). With a view to litigations about patent rights between the pharmaceutical companies involved, Eugene Goldwasser has published a very informal and personal review of the rivalry for being the first to clone the Epo gene and express rHuEpo for therapeutic purposes (49).

Human Epo is an acidic glycoprotein with a molecular mass of 30.4 kDa. The peptide core of mature Epo is composed of 165 amino acids which form two bisulphide bridges (Cys7–Cys161, Cys29–Cys33). The carbohydrate portion (40% of the molecule) comprises three tetra-antennary N-linked (Asn24, Asn38 and Asn83) and one small O-linked (Ser126) glycans (64, 65). Endogenous circulating Epo (66) as well as rHuEpo (67) have several glycosylation isoforms. The N-glycans are essential for the in vivo biological activity of Epo (68). Of major importance are the terminal sialic acid residues of these glycans (69). Like other asialo-glycoproteins, asialo-Epo is rapidly removed via galactose receptors of hepatocytes (70), because galactose is the preterminal sugar of the glycans. On the contrary, the introduction of additional N-glycans into recombinant Epo by site-directed mutagenesis results in a prolonged in vivo survival of the molecules (71, 72).

The human Epo gene is located on the long arm of chromosome 7 (q11–q22) (73–75). It contains five exons, which encode a 193-amino acid prohormone, and four introns (63). The amino acid leader sequence of 27 residues is cleaved prior to secretion (76). In addition, circulating human Epo lacks the carboxy-terminal arginine that is expected from the nucleotide sequence. Tissue-specific expression of the Epo gene depends on distinct upstream (5′) DNA sequences (77, 78). Epo expression is controlled by several transcription factors. The 5′-promoter possesses GATA-binding sites (79). GATA-4 is thought to recruit chromatin-modifying activity, promoting the expression of the Epo gene. The low GATA-4 level in adult vs. foetal hepatocytes may explain the declining role of the liver in Epo production after birth (80). In contrast to GATA-4, GATA-2 appears to inhibit Epo gene expression (81, 82). Furthermore, the Epo promoter and the 5′-flanking region contain binding sites for nuclear factor κB (NF-κB) (83). GATA-2 and NF-κB are assumed to be responsible for the inhibition of Epo gene expression in inflammatory diseases (84–86).

With respect to the hypoxic induction of Epo, of primary importance are hypoxia response elements (HRE) in the 3′-Epo enhancer to which specific heterodimeric hypoxia-inducible transcription factors (HIF-α/β) can bind. The first member of the HIF family, HIF-1, was discovered by the group of Semenza 15 yr ago (87, 88). HRE and HIF are not only relevant for Epo-producing cells but are also expressed by almost all nucleated cells (89). More than 100 genes have been identified that are regulated by HIF-binding to HRE, including those encoding the vascular endothelial growth factor (VEGF), the glucose transporters 1 and 3 and several glycolytic enzymes (90–92).

Hypoxia-inducible transcription factors cooperate with the hepatocyte nuclear factor 4 (HNF-4) (93) by direct protein–protein interaction and through the recruitment of the transcriptional co-activator complex CBP/p300 (94). A DR2 element (TGACCTCTTGACCC) near the HIF-binding site augments the hypoxic induction of Epo expression (79). DR2 elements are activated by binding the retinoic acid receptor which seems to be of major importance for Epo production by the foetal liver (95). In addition, retinoic acid has been shown to stimulate Epo production in rat kidneys and human hepatoma cell cultures (96, 97).

Hypoxic induction of Epo

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Teleologically, the primary function of Epo is to maintain the blood haemoglobin concentration in the normal range during steady-state conditions and to hasten red cell mass recovery after haemorrhage. The concentration of circulating Epo increases exponentially with decreasing haemoglobin levels in uncomplicated anaemia (absence of renal disease or inflammation). However, from the early days of Epo research it has been clear that the controlled variable is not the concentration of erythrocytes or of haemoglobin in blood. Instead, feedback regulation is based on the tissue O2 pressure (pO2), which depends on the haemoglobin concentration, the arterial pO2, the O2 affinity of the haemoglobin and the rate of blood flow. The kidney is very appropriate for controlling Epo production because the pO2 in the renal cortex is little affected by the rate of blood flow as the renal O2 consumption changes in proportion with the glomerular filtration rate (98). Whether extrarenal sites, primarily the hypothalamus (99), modulate O2-dependent Epo production in the kidney is still a matter of debate (100).

Because the tissue pO2 is the controlled variable, residence at high altitudes leads to a stimulation of erythropoiesis, and in the long term to erythrocytosis. Faura et al. (101) first demonstrated increased Epo activity in the urine of lowlanders taken to Morococha, whereby Epo activities reached peak values after 24 h and then fell to a new plateau at about twice the sea-level values. Abbrecht and Littell (102) confirmed the dynamic response by measurements of serum Epo in a high-altitude expedition in Colorado (4360 m). Note that South American high-altitude natives often suffer from erythrocytosis and chronic mountain sickness (103), while Tibetans living at about 4000 m altitude have low haemoglobin concentrations and do not develop chronic mountain sickness (104, 105). These findings are significant because they show that there has been natural selection and genetic adaptation in the evolution of tolerance of humans to hypoxia (106, 107).

The molecular mechanism of O2 sensing

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Several concepts were earlier developed to explain the pO2-dependent expression of the Epo gene [for a review, see Ref. (108)]. Based on the pioneering in vitro observation that CO suppresses Epo gene expression, while transition metal ions such as cobalt or nickel mimic the response to hypoxia, it was suggested that a haem protein might be involved in O2 sensing (109). Haemoproteins of the microsomal mixed functional oxidases (P450) were implicated in Epo production (110), which has been reconsidered recently (111). Other investigators proposed that mitochondrial reactive O2 species (ROS) might trigger hypoxia-induced transcription of the Epo gene (112). In contrast, our own group found that the production of H2O2 is reduced under hypoxic conditions (113). Studies utilising mutant cells lacking mitochondrial DNA have shown that O2 sensing does not require the mitochondrial respiratory chain apparatus for hypoxia-induced gene expression (114–116). Note, however, that ROS appear to mediate the ligand-induced activation of HIF-dependent gene expression in oxygenated cells (117).

The discovery of HIF-1 by Semenza et al. has provided a clearer insight into the molecular mechanisms of O2 sensing (87, 88). HIF-1 is a heterodimeric protein composed of the subunits α (HIF-1α, 120 kDa) and β (HIF-1β, 91–94 kDa) (118, 119), which belong to the family of basic helix loop helix Per-ARNT-Sim proteins (bHLH-PAS). The N-terminal bHLH-PAS domains are required for dimerisation and DNA-binding (120–122). Although both HIF-1α and HIF-1β are continuously translated, HIF-1α is usually not detectable in normoxic cells (123–125). The C-terminus of HIF-1α comprises a transactivation domain (TAD) that can be subdivided into an N-terminal (N-TAD) and a C-terminal (C-TAD) part. The N-TAD overlaps with an O2-dependent degradation domain (O-DDD). The critical residue in this domain is a proline in position 564 (126). Catalysed by specific prolyl-4-hydroxylases (HIF-PHD) this Pro564 is hydroxylated in the presence of O2, Fe2+ and 2-oxoglutarate (127–131). The prolyl hydroxylated HIF-1α combines with the von Hippel-Lindau tumour suppressor protein (pVHL) to form a complex that is polyubiquitinated by an E3 ligase (125, 132, 133) and undergoes immediate proteasomal degradation (134). The HIF-PHDs also catalyse the hydroxylation of a second prolyl residue (Pro402) of HIF-1α in normoxia (126).

More recently, two bHLH-PAS HIF-α isoforms have been identified, namely HIF-2α (also known as endothelial PAS domain protein 1, EPAS 1) and HIF-3α (135–138). These are also O2-labile and can dimerise with HIF-1β in hypoxia but are different with respect to their tissue-specific mRNA expression pattern (139). HIF-2α is detectable in the Epo-producing renal fibroblasts of hypoxic rats while tubular cells express HIF-1α (140, 141). Indeed, recent studies indicate that HIF-2 is the primary transcription factor inducing Epo gene expression (142). HIF-2α is degraded on hydroxylation of Pro531 (143). In contrast to HIF-1α and HIF-2α, HIF-3α lacks a transcriptional activation domain and can suppress the expression of hypoxia-responsive genes (144).

The HIF-PHDs are likely to play a major role in the control of Epo production, because they prevent HIF-α from entering the nucleus under normoxic conditions. As PHD-2 and PHD-3 are themselves HIF-target genes, their expression increases while HIF-α levels decline on exposure to hypoxia in the long term (145–147). This finding may explain the reduced Epo production during prolonged stay at high altitudes. Percy et al. (148) have recently described members of a family in whom erythrocytosis is associated with an inherited mutation in PHD-2. The binding of pVHL is a prerequisite for the degradation of HIF-α. Thus the mutation of pVHL, demonstrated in patients suffering from congenital Chuvash polycythaemia, is associated with increased transcription of the Epo gene (149).

The transcriptional activity of the HIFs is further suppressed by a third O2-dependent hydroxylation, namely at Asn803 in HIF-1α and Asn851 in HIF-2α. This reaction is catalysed by a HIF-α-specific asparaginyl hydroxylase that is also termed ‘factor-inhibiting HIF-1’ (FIH-1) (150, 151). As a result of the asparaginyl hydroxylation, the binding of the transcriptional co-activator CBP/p300 to the C-TAD of HIF-α is prevented (150, 152, 153). Like the PHDs, FIH-1 is an Fe2+-containing and α-oxoglutarate-requiring dioxygenase. On binding to Fe2+ (a non-haem iron), O2 is split with one O-atom being transferred to the amino acid residue of HIF-α and the other to α-oxoglutarate, forming CO2 and succinate. The Km values of the three PHDs for O2 are above the arterial pO2 (approximately 170 mmHg), whereas the asparaginyl hydroxylase operates at a lower pO2 (approximately 60 mmHg) (154). α-Ketoglutarate antagonists, which inhibit the hydroxylation of HIF-α (HIF stabilisers), stimulate Epo production in the kidney and the liver (155).

Fandrey (156) has recently described the molecular mechanisms controlling Epo gene expression in more detail. Reviews are also available on the role of HIF-1 and -2 activities in diseases of the cardiovascular (157) and central nervous systems (158) and in cancer (157, 159).

Erythrocytic progenitors and the Epo receptor

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Evidence was provided about 50 yr ago that blood cell production is sustained by a relatively small pool of self-renewing stem cells in haematopoietic organs. Till and McCulloch (160) showed that mouse bone marrow cells can re-populate the spleen of heavily irradiated mice to form erythrocytic, granulocytic, megakaryocytic and mixed colonies. The murine pluripotent stem cell was termed ‘colony-forming unit spleen’ (CFU-S). Subsequent studies identified subtypes of stem cells restricted to generate either myeloid or T-cell progenies (161). In the erythropoietic lineage the ‘burst-forming unit erythroid’ (BFU-E) was shown to produce large multiclustered bursts of haemoglobin-synthesising cells when cultured with high doses of Epo (162). Two different types of BFU-E were detected in mouse bone marrow: a mature type giving rise to 50–200 erythroblasts within 3 d in culture and a primitive type giving rise to several hundred erythroblasts within 8–10 d (163). The human analogues produce bursts after 10–12 and 17–20 d, respectively (164). Importantly, the primitive type of BFU-E was also detected in human blood (165, 166). The ‘colony-forming unit erythroid’ (CFU-E) was identified as a more differentiated and strictly Epo-dependent erythrocytic progenitor (163, 167). CFU-Es produce small clusters of eight to 60 erythroblasts, which takes 2–4 d for mouse (168) and 7–8 d for human cells (164). CFU-Es are not stem cells, as they have no potential for self-replication (169). The number of colonies that grow from CFU-Es correlates closely with the Epo concentration (170, 171), which can be utilised for in vitro bioassay of Epo. Koury and Bondurant (172, 173) first showed that the primary mechanism by which Epo maintains erythropoiesis is prevention of apoptosis. CFU-Es express abundant GATA-1 (174), which is an important transcription factor in erythrocytic development (175). The balance between GATA-1 and caspases determines the balance between apoptosis, proliferation and differentiation of erythrocytic progenitors (176). For example, GATA-1 was shown to induce the anti-apoptotic protein bcl-xL (177).

Chang et al. (178) and Krantz and Goldwasser (179) first provided evidence that Epo binds to a membranous receptor (Epo-R) of its target cells. The murine Epo-R was cloned and characterised by D'Andrea et al. in 1989 (180). Epo-R was found to belong to the cytokine class I receptor superfamily (181, 182) whose members are characterised by an extracellular N-terminal domain with conserved cysteines and a WSXWS-motif, a single hydrophobic transmembrane segment and a cytosolic domain that lacks enzymatic activity. The mature human Epo-R is a 484-amino acid glycoprotein with 1 N-glycan. The calculated mass of human Epo-R of 52.6 kDa increases to about 60 kDa because of glycosylation and phosphorylation (183). Two of the membrane-spanning Epo-R molecules form a homodimer that binds one Epo molecule. The Epo dissociation constants for the two Epo-R-binding sites differ by three orders of magnitude (184). Most of the ligand/Epo-R interaction occurs in a hydrophobic flat region of the Epo-R (Phe93, Met150, Phe205) (185, 186). Crystal structure analysis data of the Epo-R are available (187). With respect to novel pharmacological compounds it is of interest that the affinity of Epo analogues for Epo-R decreases with glycosylation (71). Darling et al. (188) have demonstrated that the carbohydrate portion of the glycoprotein prevents receptor binding through electrostatic forces.

Binding of Epo induces a conformational change and a tight connection of the two monomeric Epo-R molecules (189–191). Thereby, two Janus kinases 2 (JAK2) which are in contact with the cytoplasmic region of Epo-R are activated (191, 192). As a result, several tyrosine residues of the Epo-R are phosphorylated to provide docking sites for signalling proteins containing SRC homology 2 (SH2) domains (193, 194). The pathways through which Epo signals include phosphatidyl-inositol 3-kinase (PI-3K)/Akt, STAT5, MAP kinase and protein kinase C (195–197). The effect of Epo is terminated by the action of the haematopoietic cell phosphatase (HCP) which catalyses JAK2 de-phosphorylation (198, 199). Mutations of the cytoplasmic C-terminal regions of Epo-R and functional deficiencies of HCP may lead to erythrocytosis (200). In vitro studies have shown that the acute effects of Epo last for about 30–60 min (201). The Epo/Epo-R complex is internalised following de-phosphorylation of Epo-R. The proteasome controls the duration of Epo signalling by inhibiting the renewal of cell surface receptor molecules (201, 202). In using Ba/F3 and UT-7/Epo cells as in vitro model systems, Gross and Lodish (203) have recently shown that 60% of internalised Epo is re-secreted, while 40% is intracellularly degraded. It remains to be investigated, however, whether brief binding to Epo-R without internalisation suffices for Epo signalling and whether re-secreted Epo is in vivo biologically active.

Non-haematopoietic actions of Epo

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Epo-R mRNA is expressed in various non-haematopoietic tissues such as endothelium, neuronal cells and placenta (181). Probably due to anaemia and tissue hypoxia the complete knock-out of the Epo-R gene results in a phenotype of severe cardiac malformations and foetal death at day 13.5 in mice (204). Non-anaemic mice with a tissue-specific Epo-R knock-out outside the haemopoietic tissue exhibit no abnormalities (205). Functional Epo-R in non-erythrocytic cells were first demonstrated in endothelial cell cultures (206, 207). In vitro, Epo promotes the proliferation and migration of endothelial cells (206, 208), stimulates the production of modulators of vascular tone (209–211), favours a pro-angiogenic phenotype and induces neovascularisation (212). In vivo, Epo increases the number of circulating endothelial progenitor cells (213, 214). Vascular smooth muscle cells also express Epo-R (215, 216). Here, Epo causes Ca2+ mobilisation (217, 218), phospholipase C activation (219) and smooth muscle contraction (218). Other effects include the activation of the MAPK (216, 220) and PI-3K/Akt pathways (215), which mediate the inhibition of apoptosis (221, 222). Furthermore, Epo-R is expressed by human cardiomyocyte cell lines (223) and in human adult cardiac tissue (224). Preclinical studies have shown that Epo exerts cardioprotective effects (225–227).

With respect to the central nervous system both Epo-R and Epo become detectable 5 wk after conception in the brain of human embryos (228–230). Epo-R is expressed by neurones and astrocytes (231, 232) and by brain capillary endothelial cells (233, 234). Epo exerts neuroprotective and neurotrophic effects (231, 235, 236). Erbayraktar et al. (237) have reported that asialo-rHuEpo, which is devoid of erythropoiesis-stimulating activity, crosses the blood–brain barrier after i.v. administration, binds to neurones within the hippocampus and cortex, and is neuroprotective in cerebral ischaemia, spinal compression and sciatic nerve crush in experimental animals. Likewise, carbamoylated Epo (often incorrectly referred to as carbamylated Epo), which does not bind to the haematopoietic Epo-R and does not stimulate erythropoiesis (238, 239), has been reported to confer neuroprotection in animal models (240). The hypothesis has been put forward that non-haematopoietic effects of Epo are mediated by heteromers of Epo-R and β-subunit receptor molecules (240, 241). In view of the neuroprotective potential of Epo in experimental animals, Ehrenreich et al. (242) performed a clinical trial in patients with acute stroke. In a double-blind randomised proof-of-concept study of 40 patients, rHuEpo treatment showed a strong trend for reduction in infarct size as judged from magnetic resonance imaging. The reduction in infarct size correlated with a markedly improved neurologic recovery (242). rHuEpo may also prove useful as an additive neuroprotective therapeutic in schizophrenia and other human diseases characterised by a progressive decline in cognitive performance (243). Detailed reviews of the cardioprotective and neuroprotective effects of Epo are available (244–248).

A matter of current debate is whether Epo promotes tumour growth (249, 250). Epo-R mRNA and/or Epo-R protein have been detected in breast carcinoma (251–253), lung carcinoma (254), renal carcinoma (255), tumours of the cervix and of other organs of the female reproductive tract (256, 257), and various paediatric tumours (258). However, a recent study has shown that the antibodies used for detection of Epo-R protein are non-specific (259). In addition, in vitro effects of Epo in tumour cells were generally seen only when extremely high Epo concentrations were applied that exceeded the concentrations occurring after administration of Epo to oncologic patients by several orders of magnitude (251, 255, 258). Many investigators failed to demonstrate any relationship between Epo-R expression and Epo signalling or tumour growth (260–268). Liu et al. (269) have reported that Epo may not influence the basal viability of tumour cells but may prevent the cytotoxic effect of chemotherapeutics such as cisplatin. Likewise, Epo has been reported to cause resistance to cisplatin in HeLa cells (257) and to dacarbazine in melanoma cells (270). However, the understanding of the combined effects of Epo and chemotherapeutics on cancer cells is still insufficient, as one group has reported that renal carcinoma cells undergo a higher degree of apoptosis with a combination of daunorubicin and Epo or vinblastine and Epo than with either of these agents alone (271).

Anaemia of renal failure

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Richard Bright at Guy's Hospital in London is commonly credited with first having described urea retention as a cardinal sign of renal insufficiency (272). Although Bright noted ‘… after a time, the healthy colour of the countenance fades’ (272) inquirers have stated that the anaemia in association with renal failure was first recognised by Sir Robert Christison from Scotland, who stated in 1839 that ‘… by far the most remarkable character of the blood in the advanced stage of the Bright's disease is a gradual and rapid reduction of its colouring matter…’ (273). The anaemia in CKD is usually normochromic and normocytic, and its severity increases with the impairment of renal function (274, 275). Significant anaemia develops in general when the glomerular filtration rate falls below 40 to 20 mL/min and 1.73 m2 body surface area (274, 276–278). Low Epo levels relative to the degree of anaemia were first shown by bioassay (276, 279–281) and later by radioimmunoassay (274, 275, 281–284). However, the observation that the plasma Epo level can increase on acute hypoxic stress in CKD patients indicates that the capacity to produce Epo is not necessarily abolished (274). The O2 sensor in control of the synthesis of Epo appears to operate at a lower set-point in some of the patients. Epo production by the remaining renal fibroblasts may be suppressed by proinflammatory cytokines such as interleukin (IL)-1 and tumour necrosis factor (TNF)-α (285). Other factors contributing to the anaemia in CKD include shortening of red blood cell survival, bleeding, malnutrition (286), and inhibition of the growth of erythrocytic progenitors by cytokines (287, 288) and uraemia toxins (261, 282, 289, 290). A recent re-investigation into the role of cytokines has shown that T cells from poor responders to Epo therapy are in an activated state [increased expression of interferon (IFN)-γ, TNF-α, IL-10 and IL-13] and that pentoxyfilline treatment can increase haemoglobin levels in such patients (291).

Prior to the availability of rHuEpo, cobaltous salts (292, 293) and androgens (294) were used for treatment of anaemia in CKD. The molecular mechanism of the action of cobalt is not fully clear but it probably is related to HIF-α stabilisation. Exposure to industrial cobalt is thought to contribute to the erythrocytosis in high-altitude dwellers suffering from chronic mountain sickness (295). Despite the toxicity of cobalt, there is suspicion that cobalt supplementation may be misused by athletes to increase erythropoiesis (296). In contrast to cobalt, which enhances Epo production, androgens can directly stimulate the development of erythrocytic precursors (297). At least under physiological conditions, androgens do not appear to increase Epo production significantly. Treatment of men with the luteinising hormone-releasing factor agonist nafarelin results in decreased haemoglobin levels, while the concentration of Epo in plasma remains constant (298). Along these lines, the concentration of circulating Epo does not differ when female and male human beings are compared at given haemoglobin levels (299).

The erythropoietic activity of exogenous Epo in humans was first demonstrated by Oliva et al. in 1949 (23), who transfused plasma from patients with pernicious anaemia into normal subjects, and by Essers et al. in 1974 (300), who treated patients with renal failure with plasma from anaemic persons with normal kidney function. Clinical nephrology has made major progress since then, with dialysis and renal transplantation having become standard therapeutic procedures. rHuEpo was introduced as an anti-anaemic drug for treatment of CKD patients 20 yr ago (301, 302). Eschbach (303) has published a typical case report of that time: within 8 wk of rHuEpo therapy haematocrit was raised from 0.19 to 0.38 in a 39-yr-old patient with nephrotic syndrome, who had experienced androgen treatment, unsuccessful renal transplantation, transfusion of 313 units of red blood cells, and human immunodeficiency virus (HIV) infection. The patient's clinical improvement was dramatic, he was able to perform sports and to meet all the physical demands of running his country store (303). Indeed, the availability of rHuEpo has transformed the lives of hundreds of thousands of CKD patients. Epo raises haematocrit and blood haemoglobin concentration in a dose-dependent and predictable way. It abolishes the need for red cell transfusions, prevents the hyperdynamic cardiac state and improves brain function. It may also slow down the progression of chronic kidney disease (304). The target haematocrit in patients under Epo therapy is usually set at 0.33–0.36 (haemoglobin 110–120 g/L) according to the European Best Practice Guidelines (EBPG) (305) and the US-based National Kidney Foundation's Kidney Disease Outcome Quality Initiative (K/DOQI) (306). The question whether haematocrit values should be raised into the normal range has been a matter of debate (307, 308) as a randomised prospective long-term multicentre study of 1233 patients with cardiac disease showed the 1- and 2-yr mortality rates to be 7% higher in the normal haematocrit (0.42) than in the low haematocrit (0.30) group (309). A recent evidence-based systematic literature review of the relationship between haematocrit and/or haemoglobin values and all-cause mortality in dialysis patients has revealed that the published literature is insufficient for generalisation of benefits or risks of a haemoglobin level >110 to 120 g/L (310). Moreover, the just published results of the re-investigating trials Cardiovascular Risk Reduction in Early Anemia Treatment with Epoetin beta (CREATE) and Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) with Epoetin alpha support the practice to keep the patients’ haemoglobin level above the recommended level of 110 g/L and to prevent an elevation above 130 g/L (311, 312).

Causes of the rare cases of hyporesponsiveness to Epo include iron deficiency, infection and inflammation, bleeding and haemolysis, coexisting medical conditions such as malignancy, secondary hyperparathyroidism, aluminium toxicity, vitamin B12 or folate deficiency, protein malnutrition and inadequate Epo dose. Reduced iron availability is indicated by a serum ferritin concentration <100 μg/L, a transferrin saturation <20% and a proportion of hypochromic red cells >10% (313). Resistance to Epo in inflammation and infection is mainly caused by the action of IFN-γ and TNF-α (314). Measurements of C-reactive protein and baseline fibrinogen concentrations in serum may enable early recognition of the probability of response to Epo (315).

In addition to the anaemia of CKD, the anaemias associated with cancer, acquired immunodeficiency syndrome (AIDS), hepatitis C infection, bone marrow transplantation, myelodysplastic syndromes, autoimmune diseases and heart failure can be prevented by treatment with rHuEpo or its analogues (316). Miller et al. (317) first showed that the concentration of circulating Epo is relatively low in many adult cancer patients, when related to the blood haemoglobin concentration. The primary goals of Epo therapy in tumour patients are to maintain the haemoglobin values above the transfusion trigger, increase the exercise tolerance, prevent fatigue and improve quality-of-life parameters (318–320). Anti-anaemic therapy is considered beneficial for the outcome of radiotherapy and chemotherapy (321). The efficacy of the treatment of the anaemia associated with malignancy and chemotherapy is lower than in CKD patients, and higher dosing of erythropoietic drugs is required. The overall response rates have ranged from 40% to 85% (318, 322, 323). Erythropoietic stimulation in anaemic patients with chronic heart failure improves cardiac function and exercise capacity, and it reduces the need for hospitalisation (324, 325). In the surgical setting, Epo may be administered pre-operatively in order to stimulate erythropoiesis in phlebotomy programmes for autologous re-donation or for correction of a pre-existing anaemia, and post-operatively for recovery of red blood cell mass (326, 327).

Novel strategies for stimulation of erythropoiesis

  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References

Table 3 gives an overview of novel pharmacological approaches to stimulate erythropoiesis. HIF stabilisers and GATA antagonists are investigated for their potential to stimulate endogenous Epo gene expression. These compounds are orally active. The HIF stabiliser FG-2216 has already been administered in a dose-escalation study to anaemic patients with CKD (328).

Table 3.   Novel compounds and strategies for stimulation of erythropoiesis
Compound/strategy (status)Reference
HIF stabilisers for endogenous Epo gene activation (clinical studies)(328, 365)
GATA antagonists for endogenous Epo gene activation (animal studies)(86, 366)
‘Biosimilars’ (clinical studies)(329, 330)
Gene-activated Epo (Epoetin delta; clinical studies)(337, 338)
Pegylated rHuEpo (‘CERA’; clinical studies)(367)
Epo fusion proteins (animal studies)(344, 345, 345, 368–371)
Synthetic erythropoiesis proteins (SEP; animal studies)(372, 373)
Peptidic Epo mimetics (clinical studies)(186, 374, 375)
Non-peptidic Epo mimetics(376, 377)
Inhibitors of a haemopoietic cell phosphatase (animal studies)(378)
Human Epo gene therapy (clinical studies)(350)

The original rHuEpo preparations (Epoetin-α and -β) engineered in Chinese hamster ovary (CHO) cells transfected with the human Epo gene have been used routinely in clinical medicine for 20 yr. As the patents for these products have expired recently in the EU and elsewhere, other manufacturers will bring biosimilar Epoetins (‘Biosimilars’, ‘Follow-on Biologics’) on the market. The Biosimilars will have to prove that they are safe and effective (329, 330). Epoetin-omega, an rHuEpo produced in baby hamster kidney (BHK) cells has been applied in clinical trials in some countries outside the EU and the US (331–333). Note that the structure of the N-glycans of rHuEpo produced in CHO and BHK cells differs (334–336). Another new recombinant product is Epoetin-delta, which is produced by gene activation in human fibrosarcoma cells (line HT-1080) into which a DNA fragment was transfected that activates the Epo promoter (337, 338).

The rHuEpo mutein Darbepoetin-alpha was approved as an anti-anaemic drug 5 yr ago. Darbepoetin-alpha has an increased molecular mass (37.1 kDa) and an increased portion of carbohydrate (51%) compared with the Epoetins (40%). The amino acid sequence of Darbepoetin-alpha is modified by site-directed mutagenesis compared with that of the Epoetins at five positions resulting in two additional N-glycans at Asn30 and Asn88 (71). The terminal half-life of i.v. administered Darbepoetin-alpha is three- to fourfold longer than that of Epoetin-alpha and -beta [25 vs. 6–9 h; (339)]. The prolonged survival of Darbepoetin-alpha offers the opportunity for longer dosing intervals with weekly up to monthly administration. Pegylated Epoetin beta [continuous erythropoiesis receptor activator (CERA)], which is in clinical trials, has an even longer half-life (130–140 h) than Darbepoetin-alpha in circulation (340, 341). CERA contains a single methoxy-polyethylene polymer of approximately 30 kDa integrated via succidinimidyl butanoic acid. Phase I and phase II studies in healthy humans (342) respectively patients with multiple myeloma (343) have shown that CERA stimulates erythropoiesis in a dose-dependent way. Epo dimers with a polypeptide linker and Epo derivates with C-terminally added polypeptides without linker (344) and Fc-fusion proteins (345, 345) are also characterised by a prolonged half-life compared with the Epo monomers. Other pharmacological approaches such as the use of peptidic and non-peptidic organic molecules that mimic the action of Epo have been considered in detail recently (346, 347).

Epo gene therapy is an attractive alternative to the administration of erythropoietic drugs in anaemic patients (348). Here, the main problem is to adapt Epo production to the blood haemoglobin concentration. Rinsch et al. (349) first engineered cell lines to release human Epo as a function of the pO2 by using a vector containing the human Epo cDNA driven by the hypoxia-responsive phosphoglycerate kinase promoter. Lippin et al. (350) have recently performed a trial of ex vivo human Epo gene therapy in 13 CKD patients. The authors used a tissue protein factory based on dermal cores (Biopump) harvested and implanted autologously. The human Epo was expressed under the control of the cytomegalovirus (CMV) promoter. The serum Epo level increased to therapeutic levels from day 1 after implantation reaching a peak during the first week of follow-up. The rise in the Epo concentration resulted in a transient increase in reticulocyte counts. According to the authors (350) implantation of dermal cores ex vivo transduced with human genes could provide a useful tool to express therapeutic serum proteins in the clinical setting.


  1. Top of page
  2. Abstract
  3. Stimulation of erythropoiesis by hypoxaemia
  4. The search for the elusive hormone
  5. The identification of the Epo-producing organs
  6. Isolation and chemical characterisation of Epo
  7. Hypoxic induction of Epo
  8. The molecular mechanism of O2 sensing
  9. Erythrocytic progenitors and the Epo receptor
  10. Non-haematopoietic actions of Epo
  11. Anaemia of renal failure
  12. Novel strategies for stimulation of erythropoiesis
  13. Acknowledgement
  14. References
  • 1
    Maluf NS. History of blood transfusion. J Hist Med Allied Sci 1954;9:59107.
  • 2
    Bauer AW. From blood transfusion to haemotherapy – the anniversary of the German Society for transfusion medicine and immunology (DGTI) from a medicinal-historical and bioethical perspective. Transfus Med Hemother 2004;31:16.
  • 3
    Sobottka B, Eggert F, Ferstl R, Muller-Ruchholtz W. Veränderte chemosensorische Identität nach experimenteller Knochenmarktransplantation: Erkennung durch eine andere Spezies. Z Exp Angew Psychol 1989;36:65464.
  • 4
    Blundell J. Successful case of transfusion. Lancet 1828;i:4312.
  • 5
    Erslev A. Blood and mountains. In: WintrobeMM. Blood, Pure and Eloquent: A Story of Discovery, of People, and of Ideas. New York: McGraw-Hill, Inc., 1980:25780.
  • 6
    Kellogg RH. ‘‘La Pression barometrique’’: Paul Bert's hypoxia theory and its critics. Respir Physiol 1978;34:128.
  • 7
    Bert P. La Pression Barométrique. Recherches de Physiologie Expérimentale. Paris: Libraire de l'Académie de Médicine, 1878:
  • 8
    Hüfner G. Über das Gesetz der Dissociation des Oxyhaemoglobins und über einige daran sich knüpfende wichtige Fragen aus der Biologie. Arch Anat Physiol 1890; 127.
  • 9
    Viault F. Sur l'augmentation considérable du nombre des globules rouges dans le sang chez les habitants des hauts plateaux de l'Amérique du Sud. C R Acad Sci Paris 1890;111:9178.
  • 10
    Müntz A. De l'enrichissement du sang en hémoglobine, suivant les conditions d'existence. C R Acad Sci Paris 1891;112:298301.
  • 11
    Miescher F. Über die Beziehungen zwischen Meereshöhe und Beschaffenheit des Blutes. Correspondenz-Blatt Schweizer Aerzte 1893;23:80930.
  • 12
    Carnot P, Deflandre C. Sur l'activité hémopoiétique du sérum au cours de la régénération du sang. C R Acad Sci Paris 1906;143:3846.
  • 13
    Carnot MP, Deflandre C. Sur l'activité hémopoiétique des différents organes au cours de la régénération du sang. C R Acad Sci Paris 1906;143:4325.
  • 14
    Bonsdorff E, Jalavisto E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 1948;16:15070.
  • 15
    Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:44989.
  • 16
    Müller PT. Über die Wirkung des Blutserums anämischer Tiere. Arch Hygiene 1912;75:290320.
  • 17
    Mansfeld G. Blutbildung und Schilddrüse. Pflügers Arch 1913;152:2349.
  • 18
    Förster J. Luftverdünnung und Blutregeneration durch ‘‘Hämopoietine’’. Biochem Zschr 1924;145:30917.
  • 19
    Hjort E. Reticulocyttøkning efter injeksjon av ‘‘anemisk’’ serum. Norsk Mag Laegevidensk 1936;97:2707.
  • 20
    Krumdieck N. Erythropoietic substance in the serum of anemic animals. Proc Soc Exp Biol Med 1943;54:147.
  • 21
    Gunther B, Hodgson G, Tohé J, Quappe O. The inactivation by oxygen of the erithropoietic effect of plasma of rabbits rendered anemic by bleeding. Acta Physiologica Latinoamerica 1951;1:2716.
  • 22
    Fisher JW. From the elusive ‘‘hemopoietine’’ to the anti-anemic drug rErythropoietin. In: JelkmannW. Erythropoietin: Molecular Biology and Clinical Use. Johnson City, TN: FP Graham Publishing Co., 2003:332.
  • 23
    Oliva G, Chiuini F, Tramontana C. On the humoral regulation of the normoerythropoiesis. Acta Med Scand 1949;133:2730.
  • 24
    Gordon AS, Dubin M. On the alleged presence of ‘‘hemopoietine’’ in the blood serum of rabbits either rendered anemic or subjected to low pressures. Am J Physiol 1934;107:7048.
  • 25
    Feenders H. Über die hämatopoetische Wirkung des Blutserums bei sekundärer Anämie. Frankf Ztschr Path 1936;49:4117.
  • 26
    Reissmann KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood 1950;5:37280.
  • 27
    Ruhenstroth-Bauer G. Versuche zum Nachweis eines spezifischen erythropoetischen Hormons. Arch Exp Pathol Pharmakol 1950;211:3256.
  • 28
    Erslev A. Humoral regulation of red cell production. Blood 1953;8:34957.
  • 29
    Stohlman F, Rath CE, Rose JC. Evidence for a humoral regulation of erythropoiesis. Blood 1954;9:72133.
  • 30
    Schmid R, Gilbertsen AS. Fundamental observations on the production of compensatory polycythemia in a case of patent ductus arteriosus with reversed blood flow. Blood 1955;10:24751.
  • 31
    Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 1957;179:6334.
  • 32
    Gurney CW, Goldwasser E, Pan C. Studies on erythropoiesis. IV Erythropoietin in human plasma. J Lab Clin Med 1957;50:53440.
  • 33
    Gallagher NI, McCarthy JM, Hart KT, Lange RD. Evaluation of plasma erythropoietic-stimulating factors in uremic patients. Blood 1959;14:6627.
  • 34
    Kuratowska Z, Lewartowski B, Michalak E. Studies on the production of erythropoietin by isolated perfused organs. Blood 1961;18:52734.
  • 35
    Fisher JW, Birdwell BJ. The production of an erythropoietic factor by the in situ perfused kidney. Acta Haematol 1961;26:22432.
  • 36
    Gordon AS, Cooper GW, Zanjani ED. The kidney and erythropoiesis. Semin Hematol 1967;4:33758.
  • 37
    Erslev AJ. In vitro production of erythropoietin by kidneys perfused with a serum-free solution. Blood 1974;44:7785.
  • 38
    Jelkmann W, Bauer C. Demonstration of high levels of erythropoietin in rat kidneys following hypoxic hypoxia. Pflügers Arch 1981;392:349.
  • 39
    Fried W, Barone-Varelas J, Berman M. Detection of high erythropoietin titers in renal extracts of hypoxic rats. J Lab Clin Med 1981;97:826.
  • 40
    Beru N, McDonald J, Lacombe C, Goldwasser E. Expression of the erythropoietin gene. Mol Cell Biol 1986;6:25715.
  • 41
    Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 1986;6:27313.
  • 42
    Schuster SJ, Wilson JH, Erslev AJ, Caro J. Physiologic regulation and tissue localization of renal erythropoietin messenger RNA. Blood 1987;70:3168.
  • 43
    Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993;41:33541.
  • 44
    Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992;263:F47481.
  • 45
    Fandrey J, Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood 1993;81:61723.
  • 46
    Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996;8:66676.
  • 47
    Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul NT, Bartmann P, Fandrey J. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998;92:321825.
  • 48
    Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999;70:16.
  • 49
    Goldwasser E. Erythropoietin: a somewhat personal history. Persp Biol Med 1996;40:1831.
  • 50
    Plzak LF, Fried W, Jacobson LO, Bethard WF. Demonstration of stimulation of erythropoiesis by plasma from anemic rats using Fe59. J Lab Clin Med 1955;46:6718.
  • 51
    Jacobson LO, Goldwasser E, Plzak LE, Fried W. Studies on erythropoiesis. IV: Reticulocyte response of hypophysectomized and polycythemic rodents to erythropoietin. Proc Soc Exp Biol Med 1957;94:2439.
  • 52
    Cotes PM, Bangham DR. Bio-assay of erythropoietin in mice made polycythaemic by exposure to air at a reduced pressure. Nature 1961;191:10657.
  • 53
    Cotes PM, Bangham DR. The international reference preparation of erythropoietin. Bull WHO 1966;35:75160.
  • 54
    Annable L, Cotes PM, Mussett MV. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull WHO 1972;47:99112.
  • 55
    Storring PL, Gaines  Das RE. The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 1992;134:45984.
  • 56
    Garcia JF, Sherwood J, Goldwasser E. Radioimmunoassay of erythropoietin. Blood Cells 1979;5:40519.
  • 57
    Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 1982;99:62435.
  • 58
    Sherwood JB, Goldwasser E. A radioimmunoassay for erythropoietin. Blood 1979;54:88593.
  • 59
    Jelkmann W. Biochemistry and assays of Epo. In: JelkmannW. Erythropoietin: Molecular Biology and Clinical Use, 1st edn. Johnson City, TN: FP Graham Publishing Co., 2003:3563.
  • 60
    Goldwasser E, Kung CKH. Progress in the purification of erythropoietin. Ann N Y Acad Sci 1968;149:4953.
  • 61
    Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:555864.
  • 62
    Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:80610.
  • 63
    Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985;82:75804.
  • 64
    Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987;262:1205976.
  • 65
    Sasaki H, Ochi N, Dell A, Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 1988;27:861826.
  • 66
    Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 1990;76:1217.
  • 67
    Rahbek-Nielsen H., Roepstorff P, Reischl H, Wozny M, Koll H, Haselbeck A. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrometry 1997;32:94858.
  • 68
    Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985;116:22939.
  • 69
    Weikert S, Papac D, Briggs J et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999;17:111621.
  • 70
    Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989;73:909.
  • 71
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:310.
  • 72
    Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:41421.
  • 73
    Powell JS, Berkner KL, Lebo RV, Adamson JW. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 1986;83:64659.
  • 74
    Watkins PC, Eddy R, Hoffman N, Stanislovitis P, Beck AK, Galli J, Vellucci V, Gusella JF, Shows TB. Regional assignment of the erythropoietin gene to human chromosome region 7pter-q22. Cytogenet Cell Genet 1986;42:2148.
  • 75
    Law ML, Cai GY, Lin FK, Wei Q, Huang SZ, Hartz JH, Morse H, Lin CH, Jones C, Kao FT. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci USA 1986;83:69204.
  • 76
    Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 1987;262:1715663.
  • 77
    Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci USA 1991;88:87259.
  • 78
    Madan A, Lin C, Hatch SL, Curtin PT. Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 1995;85:273541.
  • 79
    Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992;12:537385.
  • 80
    Dame C, Sola MC, Lim K-C, Leach KM, Fandrey J, Ma Y, Knöpfle G, Engel JD, Bungert J. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 2004;279:295561.
  • 81
    Imagawa S, Izumi T, Miura Y. Positive and negative regulation of the erythropoietin gene. J Biol Chem 1994;269:903844.
  • 82
    Tabata M, Tarumota T, Ohmine K, Furukawa Y, Hatake K, Ozawa K, Hasegawa Y, Mukai H, Yamamoto M, Imagawa S. Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. J Cell Physiol 2001;186:2607.
  • 83
    Lee-Huang S, Lin JJ, Kung HF, Huang PL, Lee L, Huang PL. The human erythropoietin-encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements in its 5’ flanking region. Gene 1993;128:22736.
  • 84
    Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997;89:14309.
  • 85
    La Ferla K, Reimann C, Jelkmann W, Hellwig-Bürgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 2002;16:18113.
  • 86
    Nakano Y, Imagawa S, Matsumoto K et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 2004;104:43007.
  • 87
    Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991;88:56804.
  • 88
    Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:544754.
  • 89
    Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3’ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 1993;90:24237.
  • 90
    White JR, Harris RA, Lee SR, Craigon MH, Binley K, Price T, Beard GL, Mundy CR, Naylor S. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004;83:18.
  • 91
    Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:65969.
  • 92
    Allen JW, Khetani SR, Johnson RS, Bhatia SN. In vitro liver tissue model established from transgenic mice: Role of HIF1alpha on hypoxic gene expression. Tissue Eng 2006 (Epub ahead of print).
  • 93
    Galson DL, Tsuchiya T, Tendler DS, Huang LE, Ren Y, Ogura T, Bunn HF. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995;15:213544.
  • 94
    Bunn HF, Gu J, Huang LE, Park JW, Zhu H. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998;201:1197201.
  • 95
    Makita T, Hernandez-Hoyos G, Chen TH, Wu H, Rothenberg EV, Sucov HM. A developmental transition in definitive erythropoiesis: erythropoietin expression is sequentially regulated by retinoic acid receptors and HNF4. Genes Dev 2001;15:889901.
  • 96
    Okano M, Masuda S, Narita H, Masushige S, Kato S, Imagawa S, Sasaki R. Retinoic acid up-regulates erythropoietin production in hepatoma cells and in vitamin A-depleted rats. FEBS Lett 1994;349:22933.
  • 97
    Jelkmann W, Pagel H, Hellwig T, Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 1997;51:497501.
  • 98
    Erslev AJ, Caro J, Besarab A. Why the kidney? Nephron 1985;41:2136.
  • 99
    Halvorsen S. The central nervous system in regulation of erythropoiesis. Acta Haematol 1966;35:6579.
  • 100
    Von Wussow U, Klaus J, Pagel H. Is the renal production of erythropoietin controlled by the brain stem? Am J Physiol Endocrinol Metab 2005;289:E82-6.
  • 101
    Faura J, Ramos J, Reynafarje C, English E, Finne P, Finch CA. Effect of altitude on erythropoiesis. Blood 1969;33:66876.
  • 102
    Abbrecht PH, Littell JK. Plasma erythropoietin in men and mice during acclimatization to different altitudes. J Appl Physiol 1972;32:548.
  • 103
    Leon-Velarde F, Monge CC, Vidal A, Carcagno M, Criscuolo M, Bozzini CE. Serum immunoreactive erythropoietin in high altitude natives with and without excessive erythrocytosis. Exp Hematol 1991;19:25760.
  • 104
    Beall CM, Brittenham GM, Strohl KP et al. Hemoglobin concentration of high-altitude Tibetans and Bolivian Aymara. Am J Phys Anthropol 1998;106:385400.
  • 105
    Winslow RM, Chapman KW, Gibson CC, Samaja M, Monge CC, Goldwasser E, Sherpa M, Blume FD, Santolaya R. Different hematologic responses to hypoxia in Sherpas and Quechua Indians. J Appl Physiol 1989;66:15619.
  • 106
    Hochachka PW, Rupert JL, Monge C. Adaptation and conservation of physiological systems in the evolution of human hypoxia tolerance. Comp Biochem Physiol A Mol Integr Physiol 1999;124:117.
  • 107
    Hochachka PW, Gunga HC, Kirsch K. Our ancestral physiological phenotype: an adaptation for hypoxia tolerance and for endurance performance? Proc Natl Acad Sci USA 1998;95:191520.
  • 108
    Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996;76:83985.
  • 109
    Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:14125.
  • 110
    Fandrey J, Seydel FP, Siegers CP, Jelkmann W. Role of cytochrome P450 in the control of the production of erythropoietin. Life Sci 1990;47:12734.
  • 111
    Osada-Oka M, Takahashi M, Akiba S, Sato T. Involvement of Ca(2+)-independent phospholipase A(2) in the translocation of hypoxia-inducible factor-1alpha to the nucleus under hypoxic conditions. Eur J Pharmacol 2006;549:5862.
  • 112
    Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998;95:1171520.
  • 113
    Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 1994;303:50710.
  • 114
    Srinivas V, Leshchinsky I, Sang N, King MP, Minchenko A, Caro J. Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J Biol Chem 2001;276:219958.
  • 115
    Vaux EC, Metzen E, Yeates KM, Ratcliffe PJ. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 2001;98:296302.
  • 116
    Doege K, Heine S, Jensen I, Jelkmann W, Metzen E. Inhibition of mitochondrial respiration elevates oxygen concentration but leaves regulation of hypoxia-inducible factor (HIF) intact. Blood 2005;106:23117.
  • 117
    Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem 2006;387:133746.
  • 118
    Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:55104.
  • 119
    Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:12307.
  • 120
    Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:177718.
  • 121
    Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:3252937.
  • 122
    Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996;271:322539.
  • 123
    Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C117280.
  • 124
    Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:226427.
  • 125
    Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:798792.
  • 126
    Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 2001;20:5197206.
  • 127
    Epstein ACR, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:4354.
  • 128
    Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:133740.
  • 129
    Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:46872.
  • 130
    Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:4648.
  • 131
    Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001;98:96305.
  • 132
    Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J Biol Chem 1997;272:1120514.
  • 133
    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:2715.
  • 134
    Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:4237.
  • 135
    Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:7282.
  • 136
    Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii KY. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:42738.
  • 137
    Flamme I, Frohlich T, Von-Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech Dev 1997;63:5160.
  • 138
    Luo G, Gu YZ, Jain S, Chan WK, Carr KM, Hogenesch JB, Bradfield CA. Molecular characterization of the murine HIF-1α locus. Gene Expr 1997;6:28799.
  • 139
    Wiesener MS, Jurgensen JS, Rosenberger C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2002;17:2713.
  • 140
    Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002;13:172132.
  • 141
    Rosenberger C, Heyman SN, Rosen S, Shina A, Goldfarb M, Griethe W, Frei U, Reinke P, Bachmann S, Eckardt KU. Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int 2005;67:53142.
  • 142
    Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 2004;18:14624.
  • 143
    Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem 2004;92:491501.
  • 144
    Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3a in human kidney: Suppression of HIF-mediated gene expression by HIF-3a. Biochem Biophys Res Commun 2001;287:80813.
  • 145
    Del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO. Hippel Lindau/hypoxia inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 2003;278:486905.
  • 146
    Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E. Hypoxia-inducible factor-1 promotes its degradation by induction of HIF-α- Prolyl-4-Hydroxylases. Biochem J 2004;381:7617.
  • 147
    Metzen E, Stiehl DP, Doege K, Marxsen J, Hellwig-Buergel T, Jelkmann W. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 2005;387:7117.
  • 148
    Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, Lee FS. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006;103:6549.
  • 149
    Ang SO, Chen H, Hirota K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:61421.
  • 150
    Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:267586.
  • 151
    McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 2002;367:5715.
  • 152
    Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:85861.
  • 153
    Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:146671.
  • 154
    Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003;278:3077280.
  • 155
    Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW, Depinho RA, Kaelin WG Jr. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 2006;103:10510.
  • 156
    Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004;286:R97788.
  • 157
    Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:1526.
  • 158
    Freeman RS, Barone MC. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr Drug Targets CNS Neurol Disord 2005;4:8592.
  • 159
    Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors – causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004;286:R60823.
  • 160
    Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961;14:21322.
  • 161
    Abramson S, Miller RG, Phillips RA. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 1977;145:156779.
  • 162
    Iscove NN, Sieber F. Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol 1975;3:3243.
  • 163
    Gregory CJ. Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: studies of three erythropoietic colony responses in culture. J Cell Physiol 1976;89:289301.
  • 164
    Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. Blood 1977;49:85564.
  • 165
    Clarke BJ, Housman D. Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci USA 1977;74:11059.
  • 166
    Nathan DG, Chess L, Hillman DG, Clarke B, Breard J, Merler E, Housman DE. Human erythroid burst-forming unit: T-cell requirement for proliferation in vitro. J Exp Med 1978;147:32439.
  • 167
    Eaves AC, Eaves CJ. Erythropoiesis in culture. Clin Haematol 1984;13:37191.
  • 168
    Stephenson JR, Axelrad AA, McLeod DL, Shreeve MM. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA 1971;68:15426.
  • 169
    Umemura T, Papayannopoulou T, Stamatoyannopoulos G. The mechanism of expansion of late erythroid progenitors during erythroid regeneration: target cells and effects of erythropoietin and interleukin-3. Blood 1989;73:19938.
  • 170
    McLeod DL, Shreeve MM, Axelrad AA. Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E. Blood 1974;44:51734.
  • 171
    Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 1974;83:30920.
  • 172
    Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:37881.
  • 173
    Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:64963.
  • 174
    Suzuki N, Suwabe N, Ohneda O, Obara N, Imagawa S, Pan X, Motohashi H, Yamamoto M. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood 2003;102:357583.
  • 175
    Chiba T, Ikawa Y, Todokoro K. GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression. Nucleic Acids Res 1991;19:38438.
  • 176
    De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasula SM, Alnemri ES, Testa U, Peschle C. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999;401:48993.
  • 177
    Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999;94:8796.
  • 178
    Chang SC, Sikkema D, Goldwasser E. Evidence for an erythropoietin receptor protein on rat bone marrow cells. Biochem Biophys Res Commun 1974;57:399405.
  • 179
    Krantz SB, Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci USA 1984;81:75748.
  • 180
    D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989;57:27785.
  • 181
    D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990;86:6817.
  • 182
    Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:222336.
  • 183
    Elliot S, Busse L, Spahr C, Sinclair AM. Anti-EpoR antibodies detect a 59-kDa EpoR protein. Blood 2006;108:1109.
  • 184
    Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996;35:168191.
  • 185
    Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996;273:46471.
  • 186
    Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:45864.
  • 187
    Syed RS, Reid SW, Li C et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998;395:5116.
  • 188
    Darling RJ, Kuchibhotla U, Glaesner W, Micanovic R, Witcher DR, Beals JM. Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 2002;41:1452431.
  • 189
    Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 1998;5:8616.
  • 190
    Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999;283:98790.
  • 191
    Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999;283:9903.
  • 192
    Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:22736.
  • 193
    Tauchi T, Feng GS, Shen R, Hoatlin M, Bagby GC Jr, Kabat D, Lu L, Broxmeyer HE. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 1995;270:56315.
  • 194
    Barber DL, Beattie BK, Mason JM, Nguyen MHH, Yoakim M, Neel BG, D'Andrea AD, Frank DA. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood 2001;97:22307.
  • 195
    Klingmuller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells – signals emanating from the erythropoietin receptor. Eur J Biochem 1997;249:63747.
  • 196
    Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol 1998;5:1716.
  • 197
    Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 2001;7:37785.
  • 198
    Yi T, Zhang J, Miura O, Ihle JN. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 1995;85:8795.
  • 199
    Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995;80:72938.
  • 200
    Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001;68:11521.
  • 201
    Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C, Mayeux P. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000;275:1837581.
  • 202
    Supino-Rosin L., Yoshimura A, Altaratz H, Neumann D. A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem 1999;263:4109.
  • 203
    Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006;281:202432.
  • 204
    Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597605.
  • 205
    Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002;100:227988.
  • 206
    Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:597882.
  • 207
    Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:39748.
  • 208
    Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:262736.
  • 209
    Brunet P, Lorec AM, Leonetti F, Roubicek C, Jaber K, Roux F, Berland Y. Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1994;9:6504.
  • 210
    Vogel V, Kramer HJ, Backer A, Meyer-Lehnert H, Jelkmann W, Fandrey J. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997;10:28996.
  • 211
    Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int 1993;44:4305.
  • 212
    Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47:7405.
  • 213
    Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:13406.
  • 214
    Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:9216.
  • 215
    Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, Asano Y. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000;58:26982.
  • 216
    Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001;284:10318.
  • 217
    Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993;27:12336.
  • 218
    Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996;24:3927.
  • 219
    Gogusev J, Zhu DL, Herembert T, Ammarguellat F, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994;199:97783.
  • 220
    Akimoto T, Kusano E, Ito C, Yanagiba S, Inoue M, Amemiya M, Ando Y, Asano Y. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens 2001;19:193202.
  • 221
    Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:14356.
  • 222
    Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA. Role of apoptosis in reperfusion injury. Cardiovasc Res 2004;61:41426.
  • 223
    Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:9904.
  • 224
    Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, Sievers HH, Wagner KF. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:8778.
  • 225
    Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:48026.
  • 226
    Lipsic E, Van Der MP, Henning RH, Suurmeijer AJ, Boddeus KM, Van Veldhuisen DJ, Van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004;44:4739.
  • 227
    Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004;279:2065562.
  • 228
    Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996;40:37680.
  • 229
    Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:14858.
  • 230
    Dame C, Bartmann P, Wolber E-M, Fahnenstich H, Hofmann D, Fandrey J. Erythropoietin gene expression in different areas of the developing huamn central nervous system. Dev Brain Res 2000;125:6974.
  • 231
    Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:64351.
  • 232
    Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 2002;44:391403.
  • 233
    Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996;239:494500.
  • 234
    Brines ML, Ghezzi P, Keenan S, Agnello D, De Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:1052631.
  • 235
    Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:10516.
  • 236
    Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:6417.
  • 237
    Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:67416.
  • 238
    Satake R, Kozutsumi H, Takeuchi M, Asano K. Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. Biochim Biophys Acta 1990;1038:1259.
  • 239
    Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger (see comments) [published erratum appears in Science (1994) 7;263(5143):15]. Science 1993;259:3814.
  • 240
    Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:23942.
  • 241
    Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:1490712.
  • 242
    Ehrenreich H, Hasselblatt M, Dembrowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495505.
  • 243
    Ehrenreich H, Degner D, Meller J et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004;9:4254.
  • 244
    Li F, Chong ZZ, Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004;13:26589.
  • 245
    Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:20816.
  • 246
    Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83:67386.
  • 247
    Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:53848.
  • 248
    Jelkmann W. Effects of erythropoietin on brain function. Curr Pharmaceut Biotechnol 2004;6:6579.
  • 249
    Glaspy JA. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw 2005;3:796804.
  • 250
    Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:3329.
  • 251
    Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:35615.
  • 252
    Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:96981.
  • 253
    Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:9118.
  • 254
    Kayser K, Gabius HJ. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl Pathol 1992;138:26670.
  • 255
    Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:64757.
  • 256
    Yasuda Y, Musha T, Tanaka H et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001;84:83643.
  • 257
    Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789806.
  • 258
    Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:147787.
  • 259
    Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:18925.
  • 260
    Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991;63:58.
  • 261
    Mundt D, Berger MR, Bode G. Effect of recombinant human erythropoietin on the growth of human tumor cell lines in vitro. Micro-titertec-tetrazolium assay. Arzneimittelforschung 1992;42:9295.
  • 262
    Rosti V, Pedrazzoli P, Ponchio L, Zibera C, Novella A, Lucotti C, Della-Cuna GR, Cazzola M. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993;78:20812.
  • 263
    Wollman Y, Westphal G, Blum M, Simantov R, Blumberg S, Peer G, Chernihovsky T, Friedrich E, Iaina A. The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci 1996;59:31522.
  • 264
    Grossi A, Vannucchi AM, Bacci P, Caporale R, Cappelli G, Visconti G, Pagliai G, Ferrini PR. Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. Leuk Res 1998;22:14551.
  • 265
    Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, Jansen B. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:4216.
  • 266
    Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, Mattox DE. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 2001;121:14952.
  • 267
    Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:1509.
  • 268
    LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;5:34755.
  • 269
    Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004;23:98190.
  • 270
    Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:82330.
  • 271
    Carvalho G, Lefaucheur C, Cherbonnier C, Metivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F, Kroemer G. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005;24:73745.
  • 272
    Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep 1836;I:33879.
  • 273
    Hampl H, Riedel E. Zur Geschichte der renalen Anämie. Nieren- und Hochdruckkrankheiten 2002;31:53949.
  • 274
    Chandra M, Clemons GK, McVicar MI. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 1988;113:101521.
  • 275
    Pavlovic-Kentera V, Clemons GK, Trbojevic S, Dimkovic N, Djukanovic L. Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases. Nephron 1990;54:13943.
  • 276
    Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979;54:87784.
  • 277
    De Klerk G, Wilmink JM, Rosengarten PC, Vet RJ, Goudsmit R. Serum erythropoietin (ESF) titers in anemia of chronic renal failure. J Lab Clin Med 1982;100:72034.
  • 278
    McGonigle RJ, Boineau FG, Beckman B, Ohene-Frempong K, Lewy JE, Shadduck RK, Fisher JW. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 1985;105:44958.
  • 279
    Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979;93:44958.
  • 280
    Fukushima Y, Fukuda M, Yoshida K, Yamaguchi A, Nakamoto Y, Miura AB, Harada T, Tsuchida S. Serum Erythropoietin levels and inhibitors of erythropoiesis in patients with chronic renal failure. Tohoku J Exp Med 1986;150:115.
  • 281
    Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D. Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol 1986;37:3904.
  • 282
    McGonigle RJ, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984;25:4306.
  • 283
    Urabe A, Saito T, Fukamachi H, Kubota M, Takaku F. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states. Int J Cell Cloning 1987;5:2028.
  • 284
    Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int 1987;31:12059.
  • 285
    Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:5559.
  • 286
    Rosenberg ME, Howe RB, Zanjani ED, Hostetter TH. The response of erythropoietin to dietary protein in human renal disease. J Lab Clin Med 1989;113:73542.
  • 287
    Lamperi S, Carozzi S. T lymphocytes, monocytes and erythropoiesis disorders in chronic renal failure. Nephron 1985;39:2115.
  • 288
    Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003;14:177684.
  • 289
    Wallner SF, Kurnick JE, Ward HP, Vautrin R, Alfrey AC. The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis. Blood 1976;47:5619.
  • 290
    Wallner SF, Vautrin RM. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 1981;97:1708.
  • 291
    Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15:187782.
  • 292
    Weissbecker L. Die Kobalttherapie. Dtsch Med Wochenschr 1950;75:1168.
  • 293
    Kasanen A, Forsstrom J. The effect of simultaneous intramuscular ascorbic acid and cobalt therapy of renal anemia. Ann Med Exp Biol Fenn 1963;41:1035.
  • 294
    Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973;289:7280.
  • 295
    Jefferson JA, Escudero E, Hurtado ME et al. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet 2002;359:4078.
  • 296
    Lippi G, Franchini M, Guidi GC. Cobalt chloride administration in athletes: a new perspective in blood doping? Br J Sports Med 2005;39:8723.
  • 297
    Mizoguchi H, Levere RD. Enhancement of heme and globin synthesis in cultured human marrow by certain 5 -H steroid metabolites. J Exp Med 1971;134:150112.
  • 298
    Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991;36:1904.
  • 299
    Jelkmann W, Wiedemann G. Lack of sex dependence of the serum level of immunoreactive erythropoietin in chronic anemia. Klin Wochenschr 1989;67:1218.
  • 300
    Essers U, Müller W, Heintz R. Effect of erythropoietin in normal men and in patients with renal insufficiency. Proc Eur Dial Transplant Assoc 1975;11:398402.
  • 301
    Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:11758.
  • 302
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:7378.
  • 303
    Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:13448.
  • 304
    Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003;14:S1737.
  • 305
    European Renal Association-European Dialysis Transplant Association. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14:150.
  • 306
    Eknoyan G, Levin NW, Eschbach JW, Golper TA, Owen WF Jr, Schwab S, Steinberg EP. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation's Dialysis Outcomes Quality Initiative. Am J Kidney Dis 2001;37:17994.
  • 307
    Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:190814.
  • 308
    Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:73850.
  • 309
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:58490.
  • 310
    Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006;47:2436.
  • 311
    Drueke TB, Locatelli F, Clyne N, Eckardt KU, MacDougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:207184.
  • 312
    Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:208598.
  • 313
    Horl WH, Cavill I, MacDougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during r-huEPO therapy – a consensus report. Nephrol Dial Transplant 1996;11:24650.
  • 314
    Allen D, Breen C, Yaqoob M, Macdougall L. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 1999;47:20410.
  • 315
    Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993;82:20106.
  • 316
    Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:26276.
  • 317
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:168992.
  • 318
    Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:7817.
  • 319
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan RS. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:121834.
  • 320
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:341225.
  • 321
    Dunst J. Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 2000;27:48.
  • 322
    Henry DH. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994;8:96173.
  • 323
    Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 1998;15(Suppl 1):S1928.
  • 324
    Silverberg D, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:17759.
  • 325
    Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:2949.
  • 326
    Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997;336:9338.
  • 327
    Brecher ME, Goodnough LT, Monk T. Where does preoperative erythropoietin therapy count? A mathematical perspective. Transfusion 1999;39:3925.
  • 328
    Wiecek A, Piecha G, Ignacy W, Schmidt R, Neumayer HH, Scigalla P, Urquilla P. Pharmacological stabilisation of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease. Nephrol Dial Transplant 2005;20(Suppl. 5):v. 195 (Abstract).
  • 329
    Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:4347.
  • 330
    Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:95462.
  • 331
    Acharya VN, Sinha DK, Almeida AF, Pathare AV. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 1995;43:53942.
  • 332
    Bren A, Kandus A, Varl J, Buturovic J, Ponikvar R, Kveder R, Primozic S, Ivanovich P. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 2002;26:9197.
  • 333
    Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 2002;57:23745.
  • 334
    Goto M, Akai K, Murakami A et al. Production of recombinant human erythropoietin in mammalian cells: Host-cell dependency of the biological activity of the cloned glycoprotein. Bio/Technology 1988;6:6771.
  • 335
    Kawasaki N, Haishima Y, Ohta M, Itoh S, Hyuga M, Hyuga S, Hayakawa T. Structural analysis of sulfated N-linked oligosaccarides in erythropoietin. Glycobiology 2001;11:10439.
  • 336
    Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:362634.
  • 337
    Pratt R. Epoetin delta, erythropoietin produced by a human cell line, is effective in the treatment of renal anaemia. Haematologica 2006;91(S1):213 (Abstract).
  • 338
    Shahrokh Z, Flatman S, Davies M, Baycroft A, Heartlein M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic n-glycolylneuraminic acid residues. Haematologica 2006;91(S1):208 (Abstract).
  • 339
    MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:37581.
  • 340
    MacDougall IC, Bailon P, Tare N, Pahlke W, Pill J, Brandt M. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 2003;14:769 (Abstract).
  • 341
    Osterborg A. New erythropoietic proteins: rationale and clinical data. Semin Oncol 2004;31:1218.
  • 342
    Dougherty FC, Reigner B, Jordan P, Pannier A. CERA (Continuous Erythropoiesis Receptor Activator) demonstrates dose-dependent activity and is well tolerated in phase I multiple ascending dose studies. Blood 2003;102:713 (Abstract).
  • 343
    Dmoszynska A, Kloczko J, Rokicka M, Hellmann A, Spicka I, Henry D. CERA (Continuous Erythropoiesis Receptor Activator) produces a dose-related response in patients with multiple myeloma: an exploratory phase I-II dose-escalation study. Blood 2003;102:1830 (Abstract).
  • 344
    Lee DE, Son W, Ha BJ, Oh MS, Yoo OJ. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 2006;339:3805.
  • 345
    Way JC, Lauder S, Brunkhorst B et al. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 2005;18:1118.
  • 346
    MacDougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006;368:94753.
  • 347
    Bunn HF. New agents that stimulate erythropoiesis. Blood 2006; (Epub ahead of print).
  • 348
    Naffakh N, Danos O. Gene transfer for erythropoiesis enhancement. Mol Med Today 1996;2:3438.
  • 349
    Rinsch C, Regulier E, Deglon N, Dalle B, Beuzard Y, Aebischer P. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 1997;8:18819.
  • 350
    Lippin Y, Dranitzki-Elhalel M, Brill-Almon E et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005;106:22806.
  • 351
    Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005;20(Suppl 3):iii324.
  • 352
    Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:11409.
  • 353
    Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:70814.
  • 354
    Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:74654.
  • 355
    Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:345769.
  • 356
    Solberg LA Jr. Biologic aspects of thrombopoietins and the development of therapeutic agents. Curr Hematol Rep 2005;4:4238.
  • 357
    Nemunaitis J. A comparative review of colony-stimulating factors. Drugs 1997;54:70929.
  • 358
    Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:226472.
  • 359
    Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005;56:116.
  • 360
    Ringden OT, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol 2005;33:50512.
  • 361
    Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:55771.
  • 362
    Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006;46:41421.
  • 363
    Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187205.
  • 364
    Von Bultzingslowen I, Brennan MT, Spijkervet FK, Logan R, Stringer A, Raber-Durlacher JE, Keefe D. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 2006;14:51927.
  • 365
    Urquilla P, Fong A, Oksanen S et al. Upregulation of endogenous EPO in healthy sbjects by inhibition of HIF-PH. J Am Soc Nephrol 2004;15:546 (Abstract).
  • 366
    Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T, Yamamoto M. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 2003;17:17424.
  • 367
    MacDougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:43640.
  • 368
    Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998;95:11848.
  • 369
    Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274:247738.
  • 370
    Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001;97:377682.
  • 371
    Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 2006;95:193143.
  • 372
    Kochendoerfer GG, Chen SY, Mao F et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003;299:8847.
  • 373
    Chen SY, Cressman S, Mao F et al. Synthetic erythropoietic proteins: tuning biological performance by site-specific polymer attachment. Chem Biol 2005;12:37183.
  • 374
    Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997;4:93950.
  • 375
    Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege A-M. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2008;108:18304.
  • 376
    Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, Boger DL. Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 2002;124:54455.
  • 377
    Qureshi SA, Kim RM, Konteatis Z et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 1999;96:1215661.
  • 378
    Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14:8084.